SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by García-Carrasco, M.
Right arrow Articles by Font, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Carrasco, M.
Right arrow Articles by Font, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients

M. García-Carrasco

Autoimmune Diseases Unit, Instituto Mexicano del Seguro Social, Puebla, Mexico, Department of Rheumatology, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

C. Galarza

Unidad de Enfermedades Reumáticas y Autoinmunes (UNERA), Hospital Monte Sinaí, Cuenca, Ecuador

M. Gómez-Ponce

Autoimmune Diseases Unit, Instituto Mexicano del Seguro Social, Puebla, Mexico

R. Cervera

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain

J. Rojas-Rodríguez

Department of Rheumatology, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

G. Espinosa

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain, gespino{at}clinic.ub.es

S. Bucciarelli

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain

J.A. Gómez-Puerta

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain

A. Bové

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain

R.O. Escárcega

Autoimmune Diseases Unit, Instituto Mexicano del Seguro Social, Puebla, Mexico

J. Font

Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain

The objective of this study was to analyse the prevalence and characteristics of the main clinical and immunological manifestations at the onset and during the evolution of the disease in a cohort of patients from Latin America (mainly of mestizo origin) and to compare the Latin American with the European patients. Clinical and serological characteristics of 100 APS patients from Mexico and Ecuador were collected in a protocol form that was identical to that used to study the `Euro-Phospholipid' cohort. The cohort consisted of 93 female patients (93.0%) and seven (7.0%) male patients. There were 91 mestizos (91.0%), seven whites (7.0%) and two Amerindians (2.0%). The most common manifestations were livedo reticularis (40.0%), migraine (35.0%), inferior extremity deep vein thrombosis (32.0%), thrombocytopenia (28.0%) and hemolytic anemia (20.0%). Several clinical manifestations were more prevalent in Latin American than in European patients and they included mainly neurological (migraine, transient global amnesia, acute ischemic encephalopathy, amaurosis fugax) and cutaneous (livedo reticularis, skin ulcerations, superficial cutaneous necrosis, multiple subungual splinter hemorrhages) manifestations as well as hemolytic anemia. The APS has a wide variety of clinical and immunological manifestations at the onset and during the evolution of the disease and the ethnic origin in addition to environmental and socioeconomic factors can modify the disease expression. Lupus (2007) 16, 366—373.

Key Words: anticardiolipin antibodies • antiphospholipid antibodies • antiphospholipid syndrome • ethnicity • lupus anticoagulant

Lupus, Vol. 16, No. 5, 366-373 (2007)
DOI: 10.1177/0961203307077108


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
T Avcin, R Cimaz, B Rozman, and The Ped-APS Registry Collaborative Group*
The Ped-APS Registry: the antiphospholipid syndrome in childhood
Lupus, September 1, 2009; 18(10): 894 - 899.
[Abstract] [PDF]


Home page
PediatricsHome page
T. Avcin, R. Cimaz, E. D. Silverman, R. Cervera, M. Gattorno, S. Garay, Y. Berkun, F. R. Sztajnbok, C. A. Silva, L. M. Campos, et al.
Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry
Pediatrics, November 1, 2008; 122(5): e1100 - e1107.
[Abstract] [Full Text] [PDF]



Advertisement